IP Library Granted Patent US 11,897,873
Granted Patent B2
US 11,897,873 · App. 17/390,531 · Granted Feb 13, 2024

Kappa opioid receptor antagonists and products and methods related thereto

Inventors: Edward Roberts (Fallbrook, CA); Miguel A. Guerrero (San Diego, CA); Mariangela Urbano (Del Mar, CA); Hugh Rosen (La Jolla, CA); Robert M. Jones (South San Francisco, CA); Candace Mae Laxamana (South San Francisco, CA); Xianrui Zhao (South San Francisco, CA); Eric Douglas Turtle (Belmont, CA)
Assignees: BLACKTHORN THERAPEUTICS, INC.; THE SCRIPPS RESEARCH INSTITUTE
C07D413/14A61P25/00A61P25/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,897,873
App. No.
17/390,531
Granted
Feb 13, 2024
Kind
B2
Abstract

Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 and R 11 are as defined herein.

Claims (6)

1. A pharmaceutical composition comprising a compound having the following structure, or a pharmaceutically acceptable hydrate, solvate, isotope or salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient:

2. The pharmaceutical composition of claim 1 formulated for oral administration.

3. The pharmaceutical composition of claim 2 wherein the oral formulation is a tablet, capsule, troche, lozenge, syrup or emulsion.

4. The pharmaceutical composition of claim 2 wherein the oral formulation is a tablet or capsule.

5. The pharmaceutical composition of claim 3 wherein the tablet or capsule is in a dosage form for administration once a day.

6. The pharmaceutical composition of claim 3 wherein the tablet or capsule is in a dosage form for administration two or three times a day.

Assignments (1)
MERGER Recorded Aug 16, 2024
From: BLACKTHORN THERAPEUTICS, INC.
To: NEUMORA THERAPEUTICS, INC.
Reel/Frame 068318/0204 →
Continuity (6)
Continuation 16846136 · Apr 10, 2020
Division 15924119 · Mar 16, 2018
Provisional Application 62609960 · Dec 22, 2017
Provisional Application 62585447 · Nov 13, 2017
Provisional Application 62473209 · Mar 17, 2017
Related Publication 20220162202A1 · May 26, 2022